lindas have a posse
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I am sure Northwest Biotherapeutics will announce such an occasion. The fact that Dave Innes isn't tweeting BS 24/7 doesn't mean there isn't such interest in NWBO. In fact the silent confidence suggests they're not panhandling for pennies in order to continue operations.
That isn't how contract law works moreover all milestones could be completed.
Bill Gates and Jeff Bezos have family funds.
Linda Powers really doesn't need Goldman Sachs or Morgan Stanley. The dumb money have already lost.
You will know why I love Mike Scott.
Mike Scott, excellent manager!
Well said, Doc. Dave cannot say anything to individual investors as that would be an SEC RegFD violation.
Linda Powers, best CEO
Landmark Trial Results!
MHRA Trial Endorsement (PIP)!
Innovative Manufacturing!
Global Patent Protection!
My 400K shares should be worth $30M once Northwest Biotherapeutics obtains global approval on nGBM and rGBM indications.
That may take a few more years but I see no reason to sell these shares since I can borrow against them once NWBO are off OTC. I also didn't get over my skis when making investment decisions.
In my personal opinion as a retail investor representing myself alone, and not providing investment advice, the false panic created on this forum daily simply does not reflect the deep value present in Northwest Biotherapeutics stock!
Billionaire Robert Hefner agrees:
Our Northwest Biotherapeutics (NWBO) investee “partner” likely has just made one of the biggest breakthroughs in the history of cancer. We know that is a really big statement so why do we at GHK believe that is possible? Because we believe the doors through which major cancer breakthroughs must pass are the human immune system, immunotherapies and personalized vaccines and NWBO has just leaped through those doors with its personalized DCVax vaccine made from your own cells.
You can argue about trial statistics until the cows come home but the bottom line is 1) people living longer 2) quality of life during treatments and 3) the cost of treatments.
During NWBO’s 16-year Phase III trial to treat glioblastoma (GBM), one of the most difficult and lethal of all solid tumor cancers 1) more people lived longer, 2) it is safe with virtually no side effects occurring and 3) NWBO estimates treatments will cost about half as much as Standard of Care chemotherapy and radiation treatments. So for the first time ever, GBM patients can have hope! And can hope like prayer increase the effectiveness and energy of the immune system? We think so.
We are aware we stuck our necks out when we said “possibly one of the biggest breakthroughs in the history of cancer”. So we have listed below our three principle reasons so you can decide for yourself:
After 417 failed GBM trials treating 31,952 patents over decades, DCVax-L is first treatment that gives GBM patients a meaningful chance to live longer, some now living 9 to as many as 19 years and counting.
DCVax was conceived and created not for glioblastoma alone but as a personalized tool of your own immune system to defeat all solid tumor cancers and that’s 90% of all cancers.
Since DCVax’s creation NWBO has amassed an enormous rich databank containing masses of information on patients, treatments, and DCVax’s use against 15 different solid tumor cancers that has not yet been analyzed by artificial intelligence (AI). We believe that in the near future when these vast amounts of data and information are teamed with AI and some of the world’s leading scientists and doctors that future generations of DCVax vaccines and protocols will experience great leaps forward in effectiveness at lower and lower costs for 90% of all cancers.
So to sum up, we believe NWBO with its DCVax immunotherapy personalized vaccines has leaped through the doors and will play a vital role in humanities great drive to defeat cancer once and for all.
Dr. Ashkan is the genius behind this viral vid of him performing brain surgery while his patient was awakened to play the violin…mid-surgery. He told me he champions DCVax-L bc of trial data along with what he’s seen first-hand from his patients. $NWBOhttps://t.co/XFTeSPFtH5
— Wade Kovash (@wkovash) June 6, 2022
Watch one of the world’s preeminent neurosurgeons explain the significance of $NWBO ‘s Phase III trial of DCVax-L. The results are groundbreaking and represent an enormous advancement in one of the most tragic cancers. https://t.co/eQw5tAsivK
— Wade Kovash (@wkovash) June 6, 2022
Remember that NWBO are up 116% over 5 years!
XBI up only 0.2% over 5 years.
F up 27% over 5 years.
GM up 0.27% over 5 years
IBM down 5% over 5 years.
DAL down 21% over 5 years.
WBA down 46% over 5 years.
NWBO, with no revenue, performing better than entire biotech sector as well as companies with exponentially higher market caps!
How?
The market potential!
Harrison Ford still rides horses and he's 80. The bears are simply irrational.
Zero proof the milestones were unmet. All speculation otherwise by bears which have a decades-long axe to grind for Novocure's Brain Microwave.
40% of successful patents receive 1 final rejection!
https://bigpatentdata.com/2019/05/how-often-do-patent-applications-get-rejected/
Our USPTO examiner doesn't readily accept patents:
https://app.bigpatentdata.com/Examiner?id=CANELLA%2C+KAREN+A
The firm will appeal the rejection in my opinion since this isn't the end of the process.
Combination patent approved in Mexico and Israel. Globally there's around 20 million new cancer diagnoses each year. US about 1.5 million.
NWBO will appeal the final rejection in my opinion whereas no other firm has an immunotherapy which can address the all solid tumor market.
Every day closer to approval means another day to celebrate being a shareholder.
Murthy isn't key for NWBO's success.
We are easily a $50B company without Flaskworks.
We are certainly double that with Flaskworks.
It's all upside yet conjecture abounds when people want to trade or accumulate.
Perhaps all conditions were met.
Pharma should pray NWBO decides to share their technology. They have nothing but ineffective molecular poison that's losing patent protection.
I have been right every day since I bought NWBO in March 2020!
Many like to create their own missed deadlines in order to drive the price down so they can accumulate.
The only fiasco exists in your own mind. In fact I believe you and your drunken park minions manufactured the controversy out of thin air. Flaskworks are in growth mode having added two new employees in the past few months.
I trust Linda Powers who wrote NAFTA, helped author EU Patent Law, and taught at Georgetown Law.
Yes, I can see this going to SCOTUS.
The FDA should regulate this space. If you want to see the negative affects of deregulation look at the supplement industry which has a lot of ineffective products some of which are harmful.
Contract law isn't ambiguous. Murthy met his obligations or he lost his shares. I believe he's rational so wouldn't have sold his company without being able to deliver on the terms of that contract. I also trust that management would claw back compensation for non performance. We have heard nothing to suggest that occurred yet you put forward the most fantastical hypothetical scenarios which never seem to manifest. Perhaps it's the bourbon talking.
The red statement was a response to Poorman's irrational conclusions. In my opinion no way management lets Murthy leave before he's done with his work.
I didn't suggest anything negative. Quite the opposite.
Zero duty to disclose departure of employees. Did you know that Linda Powers wrote NAFTA, EU Patent Law, and taught law at Georgetown? The idea that she can secure JAMA but let Murthy bolt before delivering Flaskworks, after paying him millions in shares which dilutes her own ownership, doesn't seem logical in my personal opinion.
Do companies often PR the departure of employees?
No.
If they did the same questions would be raised regardless.
Management knows how to deliver Landmark Trial Results. They understand what it takes to manufacture an autologous dendritic cell cancer vaccine at scale. I trust they can structure an employment contract that protects shareholders, which includes management as they own hundreds of millions in warrants and shares, given they're world-class attorneys.
Did you know that Linda Powers wrote NAFTA, EU Patent Law, and taught law at Georgetown? The idea that she can secure JAMA but let Murthy bolt before delivering Flaskworks, after paying him millions in shares which dilutes her own ownership, doesn't seem logical in my personal opinion.
Certainly Murthy was under contract that stipulated milestones for his employment. Given the likely terms of the Flaskworks acquisition, he would be sued if leaving before work was complete. Or he would be forced to return his NWBO shares. He would not be able to work for a competitor nor obviously speak about his valuable contributions while at Northwest Biotherapeutics. So we are protected as shareholders. Given NWBO owns all Flaskworks IP, including the improved purity assays which Murthy helped develop, there's zero evidence of anything being amiss.
As the poster who brought the Ford Pinto analogy to this board, in reference to Novocure's Brain Microwave, I see what you're doing by coopting my apt reference to a machine which will end up atop the dust bin of oncology history. Certainly that detritus of snake oil technologies will not include Flaskworks but keep trying to frame it as a failed manufacturing process which isn't accurate by any means. There's simply no evidence to back your claims.
Drink an APA then relax. 99 problems, NWBO not one.
Buy more you will be happy in two months.
Malarkey
FDA mandated the crossover which rendered the trial not randomly controlled. Moot.
No randomly controlled trials have shown clinicial benefit for newly diagnosed or recurrent Glioblastoma patients.
The brain microwave doesn't work. Novocure is a scam which explains why their management keep dumping shares while engaging in a smear campaign against effective competitors like Northwest Biotherapeutics.
Landmark Trial Results!
MHRA Trial Endorsement (PIP)!
Innovative Manufacturing!
JAMA!
Global Patent Protection!
My 400K shares should be worth $30M once Northwest Biotherapeutics obtains global approval on nGBM and rGBM indications.
That may take a few more years but I see no reason to sell these shares since I can borrow against them once NWBO are off OTC. I also didn't get over my skis when making investment decisions.
In my personal opinion as a retail investor representing myself alone, and not providing investment advice, the false panic created on this forum daily simply does not reflect the deep value present in Northwest Biotherapeutics stock!
Billionaire Robert Hefner agrees:
Our Northwest Biotherapeutics (NWBO) investee “partner” likely has just made one of the biggest breakthroughs in the history of cancer. We know that is a really big statement so why do we at GHK believe that is possible? Because we believe the doors through which major cancer breakthroughs must pass are the human immune system, immunotherapies and personalized vaccines and NWBO has just leaped through those doors with its personalized DCVax vaccine made from your own cells.
You can argue about trial statistics until the cows come home but the bottom line is 1) people living longer 2) quality of life during treatments and 3) the cost of treatments.
During NWBO’s 16-year Phase III trial to treat glioblastoma (GBM), one of the most difficult and lethal of all solid tumor cancers 1) more people lived longer, 2) it is safe with virtually no side effects occurring and 3) NWBO estimates treatments will cost about half as much as Standard of Care chemotherapy and radiation treatments. So for the first time ever, GBM patients can have hope! And can hope like prayer increase the effectiveness and energy of the immune system? We think so.
We are aware we stuck our necks out when we said “possibly one of the biggest breakthroughs in the history of cancer”. So we have listed below our three principle reasons so you can decide for yourself:
After 417 failed GBM trials treating 31,952 patents over decades, DCVax-L is first treatment that gives GBM patients a meaningful chance to live longer, some now living 9 to as many as 19 years and counting.
DCVax was conceived and created not for glioblastoma alone but as a personalized tool of your own immune system to defeat all solid tumor cancers and that’s 90% of all cancers.
Since DCVax’s creation NWBO has amassed an enormous rich databank containing masses of information on patients, treatments, and DCVax’s use against 15 different solid tumor cancers that has not yet been analyzed by artificial intelligence (AI). We believe that in the near future when these vast amounts of data and information are teamed with AI and some of the world’s leading scientists and doctors that future generations of DCVax vaccines and protocols will experience great leaps forward in effectiveness at lower and lower costs for 90% of all cancers.
So to sum up, we believe NWBO with its DCVax immunotherapy personalized vaccines has leaped through the doors and will play a vital role in humanities great drive to defeat cancer once and for all.
Dr. Ashkan is the genius behind this viral vid of him performing brain surgery while his patient was awakened to play the violin…mid-surgery. He told me he champions DCVax-L bc of trial data along with what he’s seen first-hand from his patients. $NWBOhttps://t.co/XFTeSPFtH5
— Wade Kovash (@wkovash) June 6, 2022
Watch one of the world’s preeminent neurosurgeons explain the significance of $NWBO ‘s Phase III trial of DCVax-L. The results are groundbreaking and represent an enormous advancement in one of the most tragic cancers. https://t.co/eQw5tAsivK
— Wade Kovash (@wkovash) June 6, 2022
Agree Hoffmeister.
Shorts and spoofing market makers cannot stop DCVax!
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169815671
2,148,572 shares short yesterday. Selling isn't longs but algorithms designed to gaslight longs into giving up their pile of 24K gold for a box of lignite coal.
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169815671